{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:21:52Z","timestamp":1791591712595,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["24AARF-1192364"],"award-info":[{"award-number":["24AARF-1192364"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AG071567"],"award-info":[{"award-number":["R01AG071567"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UW ADRC P30 AG066509"],"award-info":[{"award-number":["UW ADRC P30 AG066509"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Massachusetts Alzheimer Disease Research Center","award":["P30AG062421"],"award-info":[{"award-number":["P30AG062421"]}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-21-S-TBIPH2"],"award-info":[{"award-number":["W81XWH-21-S-TBIPH2"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Allen Institute for Brain Science"},{"name":"Nancy Buster Alvord Endowment"},{"name":"Weill Neurohub Investigator program"},{"DOI":"10.13039\/100032490","name":"Freedom Together Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032490","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"DOI":"10.1007\/s00401-026-03037-y","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:47:37Z","timestamp":1781621257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neuropathological study of the effects of aducanumab anti-A\u03b2 immunotherapy on patients with Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"151","author":[{"given":"Lindsay A.","family":"Welikovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek H.","family":"Oakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Serrano-Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Ruiz-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore J.","family":"Zwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori B.","family":"Chibnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gomez-Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Frosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald S.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bernick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Latimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Matthew","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie E.","family":"Rubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bussiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Plowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Dirk","family":"Keene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley T.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"3037_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41593-025-02125-8","volume":"29","author":"G Albertini","year":"2025","unstructured":"Albertini G, Zielonka M, Cuypers ML, Snellinx A, Xu C, Poovathingal S et al (2025) The Alzheimer\u2019s therapeutic Lecanemab attenuates Abeta pathology by inducing an amyloid-clearing program in microglia. Nat Neurosci 29:100\u2013110","journal-title":"Nat Neurosci"},{"issue":"1","key":"3037_CR2","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7(1):16878","journal-title":"Sci Rep"},{"issue":"12","key":"3037_CR3","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41592-019-0582-9","volume":"16","author":"S Berg","year":"2019","unstructured":"Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, Haubold C et al (2019) ilastik: interactive machine learning for (bio)image analysis. Nat Methods 16(12):1226\u20131232","journal-title":"Nat Methods"},{"issue":"3","key":"3037_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00401-010-0719-5","volume":"120","author":"D Boche","year":"2010","unstructured":"Boche D, Denham N, Holmes C, Nicoll JA (2010) Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer\u2019s disease pathogenesis. Acta Neuropathol 120(3):369\u2013384","journal-title":"Acta Neuropathol"},{"issue":"1","key":"3037_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00401-010-0705-y","volume":"120","author":"D Boche","year":"2010","unstructured":"Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C et al (2010) Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer\u2019s disease. Acta Neuropathol 120(1):13\u201320","journal-title":"Acta Neuropathol"},{"issue":"Pt 12","key":"3037_CR6","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"D Boche","year":"2008","unstructured":"Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM et al (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain. Brain 131(Pt 12):3299\u20133310","journal-title":"Brain"},{"issue":"11","key":"3037_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","volume":"24","author":"BDC Boon","year":"2025","unstructured":"Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH et al (2025) Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study. Lancet Neurol 24(11):931\u2013944","journal-title":"Lancet Neurol"},{"issue":"2","key":"3037_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1172\/JCI23269","volume":"115","author":"RP Brendza","year":"2005","unstructured":"Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE et al (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 115(2):428\u2013433","journal-title":"J Clin Invest"},{"issue":"2","key":"3037_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al (2022) Two randomized Phase 3 studies of Aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9(2):197\u2013210","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"3037_CR10","doi-asserted-by":"publisher","first-page":"e20231363","DOI":"10.1084\/jem.20231363","volume":"221","author":"MP Cadiz","year":"2024","unstructured":"Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT et al (2024) Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med 221(2):e20231363","journal-title":"J Exp Med"},{"issue":"2","key":"3037_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-221305","volume":"93","author":"RJ Castellani","year":"2023","unstructured":"Castellani RJ, Shanes ED, McCord M, Reish NJ, Flanagan ME, Mesulam MM et al (2023) Neuropathology of Anti-Amyloid-beta Immunotherapy: a case report. J Alzheimers Dis 93(2):803\u2013813","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"3037_CR12","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/alz.13755","volume":"20","author":"T Chen","year":"2024","unstructured":"Chen T, O\u2019Gorman J, Castrillo-Viguera C, Rajagovindan R, Curiale GG, Tian Y et al (2024) Results from the long-term extension of PRIME: a randomized Phase 1b trial of aducanumab. Alzheimers Dement 20(5):3406\u20133415","journal-title":"Alzheimers Dement"},{"issue":"2","key":"3037_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70098","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou Y, Lee G, Zhong K, Fonseca J, Leisgang-Osse AM et al (2025) Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement Transl Res Clin Interv 11(2):e70098","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"3","key":"3037_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","volume":"2","author":"J Ferrero","year":"2016","unstructured":"Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O\u2019Gorman J et al (2016) First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Dement Transl Res Clin Interv 2(3):169\u2013176","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"4","key":"3037_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B et al (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer\u2019s disease. Neuron 38(4):547\u2013554","journal-title":"Neuron"},{"issue":"5","key":"3037_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.26511","volume":"92","author":"N Joseph-Mathurin","year":"2022","unstructured":"Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J et al (2022) Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited alzheimer disease. Ann Neurol 92(5):729\u2013744","journal-title":"Ann Neurol"},{"issue":"9","key":"3037_CR17","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/s41591-022-01926-9","volume":"28","author":"H Jung","year":"2022","unstructured":"Jung H, Lee SY, Lim S, Choi HR, Choi Y, Kim M et al (2022) Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein. Nat Med 28(9):1802\u20131812","journal-title":"Nat Med"},{"issue":"5","key":"3037_CR18","doi-asserted-by":"publisher","first-page":"fcac245","DOI":"10.1093\/braincomms\/fcac245","volume":"4","author":"MG Kozberg","year":"2022","unstructured":"Kozberg MG, Yi I, Freeze WM, Auger CA, Scherlek AA, Greenberg SM et al (2022) Blood-brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy. Brain Commun 4(5):fcac245","journal-title":"Brain Commun"},{"issue":"2","key":"3037_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1006\/exnr.1997.6777","volume":"150","author":"JB Leverenz","year":"1998","unstructured":"Leverenz JB, Raskind MA (1998) Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150(2):296\u2013304","journal-title":"Exp Neurol"},{"issue":"34","key":"3037_CR20","doi-asserted-by":"publisher","first-page":"10879","DOI":"10.1523\/JNEUROSCI.23-34-10879.2003","volume":"23","author":"JA Lombardo","year":"2003","unstructured":"Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ et al (2003) Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 23(34):10879\u201310883","journal-title":"J Neurosci"},{"issue":"1","key":"3037_CR21","first-page":"19","volume":"3","author":"S Love","year":"2014","unstructured":"Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K et al (2014) Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis 3(1):19\u201332","journal-title":"Am J Neurodegener Dis"},{"issue":"2","key":"3037_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.14283\/jpad.2023.6","volume":"10","author":"C Mallinckrodt","year":"2023","unstructured":"Mallinckrodt C, Tian Y, Aisen PS, Barkhof F, Cohen S, Dent G et al (2023) Investigating partially discordant results in phase 3 studies of aducanumab. J Prev Alzheimers Dis 10(2):171\u2013177","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"3037_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2990.1986.tb00053.x","volume":"12","author":"DM Mann","year":"1986","unstructured":"Mann DM, Yates PO, Marcyniuk B, Ravindra CR (1986) The topography of plaques and tangles in Down\u2019s syndrome patients of different ages. Neuropathol Appl Neurobiol 12(5):447\u2013457","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"3037_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M et al (2022) Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther 14(1):191","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"3037_CR25","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JA Nicoll","year":"2006","unstructured":"Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P et al (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65(11):1040\u20131048","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"3037_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with Amyloid-beta peptide: a case report. Nat Med 9(4):448\u2013452","journal-title":"Nat Med"},{"issue":"7","key":"3037_CR27","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/brain\/awz142","volume":"142","author":"JAR Nicoll","year":"2019","unstructured":"Nicoll JAR, Buckland GR, Harrison CH, Page A, Harris S, Love S et al (2019) Persistent neuropathological effects 14 years following Amyloid-beta immunization in Alzheimer\u2019s disease. Brain 142(7):2113\u20132126","journal-title":"Brain"},{"issue":"1","key":"3037_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey ED, Bussiere T, Rajagovindan R, Sebalusky J, Hamann S, von Hehn C et al (2022) Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol 144(1):143\u2013153","journal-title":"Acta Neuropathol"},{"issue":"6","key":"3037_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-014-1340-9","volume":"128","author":"K Sakai","year":"2014","unstructured":"Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S et al (2014) Abeta immunotherapy for Alzheimer\u2019s disease: effects on apoE and cerebral vasculopathy. Acta Neuropathol 128(6):777\u2013789","journal-title":"Acta Neuropathol"},{"issue":"Pt 5","key":"3037_CR30","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/brain\/awq056","volume":"133","author":"A Serrano-Pozo","year":"2010","unstructured":"Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA et al (2010) Beneficial effect of human anti-Amyloid-beta active immunization on neurite morphology and tau pathology. Brain 133(Pt 5):1312\u20131327","journal-title":"Brain"},{"issue":"7618","key":"3037_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature 537(7618):50\u201356","journal-title":"Nature"},{"issue":"6","key":"3037_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"issue":"3","key":"3037_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC et al (2012) Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11(3):241\u2013249","journal-title":"Lancet Neurol"},{"issue":"721","key":"3037_CR34","doi-asserted-by":"publisher","first-page":"eadk9993","DOI":"10.1126\/scitranslmed.adk9993","volume":"15","author":"GT Tabor","year":"2023","unstructured":"Tabor GT, Holtzman DM (2023) Current status of amyloid-targeting immunotherapies for Alzheimer\u2019s disease. Sci Transl Med. 15(721):eadk9993","journal-title":"Sci Transl Med."},{"issue":"8","key":"3037_CR35","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/jnen\/59.8.733","volume":"59","author":"DR Thal","year":"2000","unstructured":"Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K et al (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59(8):733\u2013748","journal-title":"J Neuropathol Exp Neurol"},{"issue":"17","key":"3037_CR36","first-page":"1631","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Sabbagh M, Cohen S (2023) Lecanemab in early Alzheimer\u2019s disease. Reply. N Engl J Med 388(17):1631\u20131632","journal-title":"N Engl J Med"},{"issue":"5","key":"3037_CR37","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41591-025-03574-1","volume":"31","author":"L van Olst","year":"2025","unstructured":"van Olst L, Simonton B, Edwards AJ, Forsyth AV, Boles J, Jamshidi P et al (2025) Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer\u2019s disease. Nat Med 31(5):1604\u20131616","journal-title":"Nat Med"},{"issue":"5","key":"3037_CR38","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-023-02631-8","volume":"146","author":"L VandeVrede","year":"2023","unstructured":"VandeVrede L, La Joie R, Horiki S, Mundada NS, Koestler M, Hwang JH et al (2023) Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with Aducanumab. Acta Neuropathol 146(5):777\u2013781","journal-title":"Acta Neuropathol"},{"issue":"4","key":"3037_CR39","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/brain\/awae345","volume":"148","author":"LA Welikovitch","year":"2025","unstructured":"Welikovitch LA, de Mate Gerando A, Khasnavis A, Bhavsar H, Meltzer JC, Buee L et al (2025) Tau, synapse loss and gliosis progress in an Alzheimer\u2019s mouse model after amyloid-beta immunotherapy. Brain 148(4):1316\u20131328","journal-title":"Brain"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-026-03037-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-026-03037-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-026-03037-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:47:39Z","timestamp":1781621259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-026-03037-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["3037"],"URL":"https:\/\/doi.org\/10.1007\/s00401-026-03037-y","relation":{},"ISSN":["1432-0533"],"issn-type":[{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SS is a consultant for Amylyx, Alnylam, Biogen, Bolden, Eisai, Eli Lilly, Genentech, NovoNordisk, Ono, Prothena, and Roche. CB serves on the scientific advisory board for NovoNordisk. DG was the Chief Medical Officer for AriBio from 2023\u20132024. RMH is an employee and shareholder of Biogen. CER is an employee and shareholder of Biogen. TB is a former employee and shareholder of Biogen. EDP is an employee and shareholder of Biogen. BTH serves on a scientific advisory board or is a consultant for AbbVie, Alexion, Ambagon, Aprinoia Therapeutics, Arbor Bio, Arvinas, Avrobio, AstraZenica, Biogen, Bioinsights, BMS, Cell Signaling, Cure Alz Fund, CurieBio, Dewpoint, Eisai, Etiome, Latus, Merck, Novartis, Paragon, Pfizer, Sanofi, Sofinnova, SV Health, Takeda, TD Cowen, Vigil, Violet, Voyager, WaveBreak; his laboratory is supported by research grants from the National Institutes of Health, Cure Alzheimer\u2019s Fund, Tau Consortium, and the JPB Foundation\u2014and a sponsored research agreement from Abbvie and Sanofi; he has a collaborative project with Biogen and Neurimmune AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"68"}}